Evolent Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Evolent Health, Inc. on December 21, 2020. The report discloses corporate governance actions regarding executive compensation arrangements rather than financial performance results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on the approval of severance and change in control arrangements for specific officers.
Material Changes
On December 21, 2020, the Board of Directors' Compensation Committee approved new severance and change in control arrangements for the following "Covered Executives":
- Frank Williams (Executive Chair)
- Seth Blackley (Chief Executive Officer)
- John Johnson (Chief Financial Officer)
- Jonathan Weinberg (General Counsel)
These arrangements define benefits payable upon involuntary termination without cause or resignation for "good reason," distinguishing between terminations occurring outside a change in control ("Non-CIC") and those occurring in connection with or within 24 months of a change in control ("CIC").
Guidance, Outlook, and Management Commentary
The filing details the specific terms of the approved arrangements:
- Non-CIC Qualifying Termination: Executives receive cash payments equal to base salary for 12 months (Johnson, Weinberg) or 18 months (Williams, Blackley). They also receive a pro-rated bonus, credited service time for unvested equity, and COBRA subsidies.
- CIC Qualifying Termination: Executives receive a lump sum cash payment equal to 1.5x (Johnson, Weinberg) or 2x (Williams, Blackley) of their annual base salary plus target bonus. Unvested time-based equity awards vest in full, and performance-based awards vest at the greater of target or actual performance. COBRA subsidies are also provided.
The arrangements were approved following a review of peer and industry practices by an independent compensation consultant.
Investor Verification Checklist
- Verify the specific base salary and target bonus figures for the Covered Executives to calculate potential severance liabilities.
- Review the Company's existing equity award plans to understand the impact of accelerated vesting on dilution.
- Assess the likelihood of a change in control event given the enhanced severance terms.
- Confirm if these arrangements were disclosed in prior proxy statements or if this represents a material amendment.